

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Pratt**

Application No.: **Not Yet Assigned**

Filed: **HEREWITH**

For: **Liquid Dosage Formulations of Donepezil**

Docket No: 109563.183

Assistant Commissioner of Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 Form.


The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

Pursuant to 37 CFR § 1.98(d), the documents listed on the attached PTO-1449 form are not being submitted herewith since they were previously cited and/or submitted in the parent application and/or grandparent application, to which the present application claims priority.

This Information Disclosure Statement is being submitted before the mailing date of a first office action on the merits or a notice of allowance. Accordingly, no fee is due.

Applicants respectfully request that the Examiner initial and return a copy of the enclosed PTO-1449 Form with the next communication from the Patent Office.

Respectfully submitted,


Edward D. Gieff
Registration No. 38,898

Date: July 22, 2003
HALE and DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: (202) 942-8400

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Applicati n Number		
			Filing Date		
			First Named Inventor	Pratt	
			Group Art Unit		
			Examiner Name		
Sheet	1	of	2	Attorney Docket Number	109536.162 US2

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Completeness if Known			
		Application Number			
		Filing Date			
		First Named Inventor	Pratt		
		Group Art Unit			
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	109536.162 US2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., American Psychiatric Association, pages 163-164 (2000)	
		Mendez et al, Journal of Neuropsychiatry and Clinical Neuroscience, 11(2):268-270 (1999).	
		Hasegawa et al, Folia Pharmacologica Japonica, 114(6):327-336 (December 1999).	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.